Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection.
Horsmans Y, Colle I, Van Vlierberghe H, Langlet P, Adler M, Bourgeois N, Brenard R, Michielsen P, Goossens A, Bruckers L; Belgian Assocation for the Study of the Liver. Horsmans Y, et al. Among authors: bruckers l. Acta Gastroenterol Belg. 2008 Jul-Sep;71(3):293-7. Acta Gastroenterol Belg. 2008. PMID: 19198574 Clinical Trial.
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
Van Vlierberghe H, Leroux-Roels G, Adler M, Bourgeois N, Nevens F, Horsmans Y, Brouwer J, Colle I, Delwaide J, Brenard R, Bastens B, Henrion J, de Vries RA, de Galocsy C, Michielsen P, Robaeys G, Bruckers L. Van Vlierberghe H, et al. Among authors: bruckers l. J Viral Hepat. 2003 Nov;10(6):460-6. doi: 10.1046/j.1365-2893.2003.00466.x. J Viral Hepat. 2003. PMID: 14633181 Clinical Trial.
Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks.
Robaeys G, De Bie J, Wichers MC, Bruckers L, Nevens F, Michielsen P, Van Ranst M, Buntinx F. Robaeys G, et al. Among authors: bruckers l. World J Gastroenterol. 2007 Nov 21;13(43):5736-40. doi: 10.3748/wjg.v13.i43.5736. World J Gastroenterol. 2007. PMID: 17963300 Free PMC article. Clinical Trial.
Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.
Robaeys G, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F; BASL Steering Committee; Benelux Study Group. Robaeys G, et al. Among authors: bruckers l. Eur J Gastroenterol Hepatol. 2006 Feb;18(2):159-66. doi: 10.1097/00042737-200602000-00008. Eur J Gastroenterol Hepatol. 2006. PMID: 16394797 Clinical Trial.
Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
Arain A, Bourgeois S, de Galocsy C, Henrion J, Deltenre P, d'Heygere F, George C, Bastens B, Van Overbeke L, Verrando R, Bruckers L, Mathei C, Buntinx F, Van Vlierberghe H, Francque S, Laleman W, Moreno C, Janssens F, Nevens F, Robaeys G. Arain A, et al. Among authors: bruckers l. J Med Virol. 2016 Jan;88(1):94-9. doi: 10.1002/jmv.24308. Epub 2015 Jul 21. J Med Virol. 2016. PMID: 26121975
On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
Busschots D, Bielen R, Koc ÖM, Heyens L, Dercon E, Verrando R, Janssens F, Van den Bergh L, Van Lint P, Bruckers L, Nevens F, Robaeys G. Busschots D, et al. Among authors: bruckers l. BMC Public Health. 2021 Aug 20;21(1):1574. doi: 10.1186/s12889-021-11608-9. BMC Public Health. 2021. PMID: 34416867 Free PMC article.
139 results